Amy S. Clark, MD, MSCE
Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-154
3400 Civic Center Boulevard
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-154
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-662-7096
Fax: 215-615-3349
Fax: 215-615-3349
Email:
amy.clark@uphs.upenn.edu
amy.clark@uphs.upenn.edu
Education:
BS (Biology)
Haverford College, 1999.
MD (Medicine)
Milton S. Hershey Penn State College of Medicine, 2006.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2012.
Permanent linkBS (Biology)
Haverford College, 1999.
MD (Medicine)
Milton S. Hershey Penn State College of Medicine, 2006.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2012.
Description of Clinical Expertise
I am a medical oncologist who specializes in breast cancer. I only see breast cancer patients in the outpatient setting, but treat patients will all cancers when working in the hospital.Description of Research Expertise
My research focuses on clinical trials and drug development for those with early stage and metastatic breast cancer. I also seek to develop novel predictive biomarkers specifically using molecular imaging as companions to early phase trials.Selected Publications
Swain S, Tang G, Puhalla SL, Ganz PA, Henry NL, Cecchini RS, Reid SA, Rastogi P, Geyer CE, White JR, Clark AS, Haddad TC, Vidal GA, Wolmark N, Mamounas EP: A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009. Annual Meeting of the American Society of Clinical Oncology, Chicago, IL. Jun 2024 Notes: "Poster Presentation"Giridhar, K., Clark, A: Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC). Annual Meeting of the American Society of Clinical Oncology, Chicago, IL. Jun 2024 Notes: "Poster Presentation"
Slavkova KP, McDonald ES, Cohen EA, Pantalone L, Bayne L, Nivar I, Sanchez P, Mankowski WC, Brown M, Clark AS, Rohn K, Chodosh LA, Kontos D, DeMichele A: Evaluating the association between radiomic features on breast MRI and dormant tumor cell presence in the SURMOUNT Trial. Annual Meeting of the American Society of Clinical Oncology, Chicago, IL. Jun 2024 Notes: "Poster Presentation"
Zhang, H., Clark, A.S., : A quantitative bias analysis approach to informative presence bias in electronic health records. Epidemiology 35(3): 349-358, May 2024.
Albain K, Yau C, Petricoin E, Wolf D, Lang J, Chien A, Haddad T, Forero-Torres A, Wallace A, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias A, Clark A, Godellas C, Boughey J, Isaacs C, Tripathy D, Lu J, Yung R, Gallagher R, Wulfkuhle J, Swigart LB, Krings G, Chen YY, Potter D, Stringer-Reasor E, Blair S, Asare S, Wilson A, Hirst G, Singhrao R, Buxton M, Clennell J, Sanil A, Berry S, Asare A, Matthews J, DeMichele A, Hylton N, Melisko M, Perlmutter J, Rugo H, Symmans W, Van't Veer L, Yee D, Berry D, Esserman L: Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial — Efficacy and biomarker discovery. Clinical Cancer Research. (eds.). 30(4): 729-40, Feb 2024.
Lynce, F., Stevens, L. E., Li, Z., Brock, J. E., Gulvady, A., Huang, Y., Nakhlis, F., Patel, A., Force, J. M., Haddad, T. C., Ueno, N., Stearns, V., Wolff, A. C., Clark, A. S., Bellon, J. R., Richardson, E. T., Balko, J. M., Krop, I. E., Winer, E. P., Lange, P., Hwang E. S., King, T. A., Tolaney, S. M., Thompson, A., Gupta, G. P., Mittendorf, E. A., Regan, M. M., Overmoyer, B., Polyak, K: TBCRC 039: A phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer. Breast Cancer Research (eds.). 26(1): 20, Jan 2024.
Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky KM, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Torres ETR, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Yi Chen Y, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood M, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van ‘t Veer LJ, Hylton NM, Esserman LJ. : Safety and efficacy of datopotamab-deruxtecan plus durvalumab in the I-SPY2.2 Sequential Multiple Assignment Randomized Trial. Nature Medicine 2024 Notes: Accepted for Publication.
Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien J, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Torres ETR, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van ‘t Veer LJ, Hylton NM, Esserman LJOuthaythip, Wen Li, Natsuko Onishi, Adam L. Asare, Philip Beineke, Peter Norwood, Lamorna Brown-Swigart, Gillian L. Hirst, Jeffrey B. Matthews, Brian Moore, W. Fraser Symmans, Elissa Price, Carolyn Beedle, Jane Perlmutter, Paula Pohlmann, Rebecca A. Shatsky, Angela DeMichele, Douglas Yee, Laura J. van ‘t Veer, Nola M. Hylton, Laura J. Esserman: Datopotamab-deruxtecan in early-stage breast cancer: the phase 2 I-SPY2.2 sequential multiple assignment randomized trial. Nature Medicine 2024 Notes: Accepted for Publication.
Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chein AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, Isaacs CJ, Nanda R, Han HS, Yung RL, Tripathy D, Edminston KK, Viscusi RK, Northfelt DW, Khan QJ, Asare SM, Wilson A, Hirst GL, Lu R, Symmans WF, Yee D, DeMichele A, Van't Veer LJ, Esserman LJ, Olopade OI: Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer. JAMA Network Open 6(12): e2349646, Dec 1 2023.
Amy S. Clark.: NRG-BR009: Phase III Trial Evaluating Addition of Adjuvant Chemotherapy to Ovarian Function Suppression + Endocrine Therapy in Premenopausal Women with pN0-1, HR+/HER2- Breast Cancer and Oncotype Recurrence Score ≤25 (OFSET). San Antonio Breast Cancer Symposium BR009 Spotlight, San Antonio, TX. Dec 2023 Notes: "Oral Presentation"